og:image: https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png
twitter:card: summary
og:site_name: PubMed
keywords: pmid:36622366, doi:10.1042/BSR20222102, Research Support, Non-U.S. Gov't, Vasudha Tandon, Rita Moreno, Sourav Banerjee, Gene Expression Regulation, Humans, Neoplasms*, Phosphorylation, Proteasome Inhibitors / pharmacology, Transcription Factors / genetics, Transcription Factors / metabolism, PubMed Abstract, NIH, NLM, NCBI, National Institutes of Health, National Center for Biotechnology Information, National Library of Medicine, MEDLINE
twitter:url: https://pubmed.ncbi.nlm.nih.gov/36622366/
citation_journal_title: Bioscience reports
ncbi_pdid: abstract
ncbi_phid: 579300011145644500002FF4104494B6.1.m_5
og:description: Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a trac ?
og:image:secure_url: https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png
ncbi_db: pubmed
citation_issn: 1573-4935
ncbi_pinger_stat_url: https://www.ncbi.nlm.nih.gov/stat
dc:title: Dual inhibition of HSF1 and DYRK2 impedes cancer progression - PubMed
log_category: literature
Content-Encoding: UTF-8
robots: index,nofollow,noarchive
twitter:domain: pubmed.ncbi.nlm.nih.gov
log_icons_present: true
log_op: retrieve
citation_abstract_html_url: https://pubmed.ncbi.nlm.nih.gov/36622366/
citation_issue: 1
log_source_db: pubmed
log_displayeduids: 36622366
ncbi_uid: 36622366
citation_doi: 10.1042/BSR20222102
citation_volume: 43
Content-Language: en
theme-color: #20558a
citation_title: Dual inhibition of HSF1 and DYRK2 impedes cancer progression
ncbi_sg_optimize_id: 
citation_publisher: Biosci Rep
HandheldFriendly: True
description: Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a trac ?
citation_date: 01/31/2023
title: Dual inhibition of HSF1 and DYRK2 impedes cancer progression - PubMed
ncbi_cost_center: pubmed
twitter:image: https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png
uid: 36622366
ncbi_pinger_gtm_track: true
Content-Type: text/html; charset=UTF-8
X-Parsed-By: org.apache.tika.parser.DefaultParser
og:type: website
twitter:title: Dual inhibition of HSF1 and DYRK2 impedes cancer progression - PubMed
citation_pmid: 36622366
ncbi_app: pubmed
og:title: Dual inhibition of HSF1 and DYRK2 impedes cancer progression - PubMed
citation_authors: Tandon V;Moreno R;Allmeroth K;Quinn J;Wiley SE;Nicely LG;Denzel MS;Edwards J;de la Vega L;Banerjee S;
X-UA-Compatible: IE=edge
referrer: origin-when-cross-origin
MobileOptimized: 320
viewport: width=device-width, initial-scale=1.0
twitter:description: Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a trac ?
og:url: https://pubmed.ncbi.nlm.nih.gov/36622366/